Imexpharm Corporation

HOSE:IMP Stock Report

Market Cap: ₫7.4t

Imexpharm Past Earnings Performance

Past criteria checks 5/6

Imexpharm has been growing earnings at an average annual rate of 12%, while the Pharmaceuticals industry saw earnings growing at 5.3% annually. Revenues have been growing at an average rate of 11.1% per year. Imexpharm's return on equity is 14.7%, and it has net margins of 13.5%.

Key information

12.0%

Earnings growth rate

11.2%

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth rate11.1%
Return on equity14.7%
Net Margin13.5%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Imexpharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

HOSE:IMP Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 242,205,120297,536610,7310
30 Sep 242,161,215229,628611,9360
30 Jun 242,083,396226,924589,2610
31 Mar 242,005,866240,873590,7190
31 Dec 231,994,037254,623602,9260
30 Sep 231,943,044262,780520,3740
30 Jun 231,893,973248,864521,9810
31 Mar 231,808,733212,500577,7690
31 Dec 221,643,707183,844523,0550
30 Sep 221,483,063193,294435,5630
30 Jun 221,321,432168,823393,0800
31 Mar 221,284,405176,146373,9750
31 Dec 211,266,597173,513362,8680
30 Sep 211,357,095173,320398,6460
30 Jun 211,390,894192,894404,5110
31 Mar 211,362,172184,242372,3340
31 Dec 201,369,422179,658356,7630
30 Sep 201,398,480164,014380,7310
30 Jun 201,436,011154,636399,0440
31 Mar 201,432,983145,354423,3440
31 Dec 191,402,454142,900436,0160
30 Sep 191,261,051131,865404,6850
30 Jun 191,230,077125,694399,7400
31 Mar 191,204,780124,885408,6090
31 Dec 181,184,818122,041387,1770
30 Sep 181,224,760112,394415,0070
30 Jun 181,178,882106,176402,2240
31 Mar 181,194,327109,745408,6900
31 Dec 171,165,456103,277415,3290
30 Sep 171,116,855110,222442,7380
30 Jun 171,081,387104,160444,4870
31 Mar 171,041,96790,389419,2880
31 Dec 161,010,34688,009372,1320
30 Sep 16979,58775,696231,3410
30 Jun 16948,20870,215209,2750
31 Mar 16941,85778,639261,5290
31 Dec 15964,31981,760265,9380
30 Sep 15935,08581,196326,3940
30 Jun 15968,85384,855362,3800
31 Mar 15937,56176,918305,2630
31 Dec 14897,13672,933310,3560
30 Sep 14825,30553,276285,2420
30 Jun 14809,11051,677273,4470
31 Mar 14830,00755,051278,5910

Quality Earnings: IMP has high quality earnings.

Growing Profit Margin: IMP's current net profit margins (13.5%) are higher than last year (12.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IMP's earnings have grown by 12% per year over the past 5 years.

Accelerating Growth: IMP's earnings growth over the past year (16.9%) exceeds its 5-year average (12% per year).

Earnings vs Industry: IMP earnings growth over the past year (16.9%) exceeded the Pharmaceuticals industry -13.4%.

Return on Equity

High ROE: IMP's Return on Equity (14.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/15 17:55
End of Day Share Price 2025/02/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Imexpharm Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Minh DangSSI Securities Corporation
Quan CaoViet Dragon Securities Corporation